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Abstract 
Background: The severity and outcome of malaria is influenced by host immunity in which chemokines such as 
Regulated upon Activation, Normal T cell Expressed and Secreted (RANTES) play an important role. Previous studies 
show that variations in the RANTES gene affect RANTES protein production, hence altering host immunity. In this 
study, the relationship between presence of mutations in RANTES and incidence of malaria in a cohort of children liv-
ing in a malaria-endemic area of Uganda was determined.
Methods: This was a longitudinal study comprising of 423 children aged between 6 months and 9 years, who were 
actively followed up for 1 year. Malaria episodes occurring in the cohort children were detected and the affected 
children treated with national policy drug regimen. Mutations in the RANTES gene were determined by PCR–RFLP 
method and their frequencies were calculated. A multivariate negative binomial regression model was used to esti-
mate the impact of RANTES mutations on malaria incidence. In all statistical tests, a P-value of <0.05 was considered as 
significant.
Results: The frequencies of the −403A and In1.1C allele were 53.7 and 19.2 %, respectively. No mutations were 
found at the −28 locus. After adjustment of incidence rates for age, blood group, insecticide-treated bed net (ITN) 
use, malaria history and the sickle cell trait, 1n1.1T/C heterozygotes and homozygotes showed a non-significant trend 
towards higher incidence rates compared to wild-type individuals (IRR = 1.10; P = 0.55 and IRR = 1.25; P = 0.60, 
respectively). Similarly, there was no significant difference in malaria incidence rates between RANTES −403G/A het-
erozygotes or homozygotes and those without mutations (IRR = 1.09; P = 0.66 and IRR = 1.16; P = 0.50, respectively). 
No relation was seen between RANTES polymorphisms, baseline parasite densities and the time to first re-infection 
after administration of anti-malaria drugs.
Conclusions: This study showed that the −403A mutation occurs in nearly half of the study population and the 
In1.1C allele occurs in one in every four children. Despite the high frequency of these mutations, there was no clear 
association with malaria incidence. Other studies evaluating more markers, that could potentially modulate RANTES 
gene transcription alongside other genetic modifiers of malaria susceptibility, may provide further explanations to 
these less dramatic findings.
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Background
Plasmodium falciparum malaria accounts for approxi-
mately 198 million clinical cases of malaria worldwide 
and 584,000 deaths annually [1]. A majority of these 
deaths occur in sub Saharan Africa, with over 78  % of 
all deaths happening in children under 5 years of age [1]. 
The development of naturally acquired immunity takes 
time and is associated with increasing age, which cor-
relates with a reduction in mortality rates arising from 
severe forms of P. falciparum infection [2]. The devel-
opment of this immunity still remains a mystery and as 
to why malaria episodes occur more frequently in some 
children compared to others raises further questions. 
Host genetic factors play an important role in reducing 
the risk to Plasmodium infection. The protective effect of 
the sickle cell trait (Hb AS) against both uncomplicated 
and severe malaria disease has been well documented 
[3–8]. It is, therefore, important to examine different host 
factors in order to further define their association with P. 
falciparum infection.
Regulatory cytokines and other mediators have also 
been reported to play a critical role in controlling para-
sitaemia and subsequent elimination of infection. Inter-
feron-gamma (IFN γ), tumor necrosis factor (TNF), 
Interleukin 10 (IL-10), IL-17, IL-4, C–C chemokine 
RANTES (Regulated upon Activation, Normal T cell 
Expressed and Secreted), matrix metalloproteinases 8 
(MMP8s) and tissue inhibitor of metalloproteinases 1 
(TIMP1) have been linked to disease severity in malaria-
infected individuals [9–16]. The mechanism of this 
immune modulation involves activation of leukocytes, 
recruitment of leukocytes and Plasmodium-infected 
erythrocytes causing occlusion of blood vessels, degra-
dation of cell–cell junctions, blood–brain barrier dys-
function, interfering with formation of blood vessels and 
formation of blood cells or haematopoiesis [11, 12, 17–
21]. Previous studies have shown that variations in the 
RANTES gene affect RANTES protein production and 
the subsequent host immune response towards a variety 
of infections [22, 23]. Low levels of the RANTES protein 
have also been observed in severe malaria due to acqui-
sition of Plasmodium haemozoin by monocytes [24] or 
malaria-induced thrombocytopaenia [11] and have been 
associated with mortality among children with cerebral 
malaria [12].
The human RANTES gene is located on chromo-
some 17q11.2-q12, has a genomic size of 8.8  kb and 
encodes a protein of 8 kDa [22]. Among the several sin-
gle nucleotide polymorphisms (SNPs) in the RANTES 
gene that have been reported before, the −403G/A and 
the −28C/G nucleotides located in the promoter region, 
along with the InI.1T/C present in the first intron, are 
the most polymorphic and appear to modify RANTES 
transcription [22]. The RANTES −28G variant was found 
to up-regulate RANTES expression in vitro [22, 23] and 
to be associated with delayed disease progression among 
HIV-infected adults [23, 25–27]. The In1.1C variant, 
which also occurs in strong linkage disequilibrium with 
−403 A allele, was associated with reduced RANTES 
transcription activity in  vitro [22] and increased rate of 
AIDS progression [22, 28, 29], but was found to be pro-
tective against disease progression among Ugandan HIV 
adults [30]. The prevalence of these RANTES polymor-
phisms varies in different populations. The −403 A allele 
occurs predominantly among African populations [22, 
28, 30], while the −28G allele is found to be more preva-
lent among Japanese [31] and Han Chinese populations 
[23], but scarcely distributed among Caucasians and Afri-
can populations [22, 30]. RANTES levels were also found 
to vary by race with low values prevailing among African 
populations compared to Caucasians [32].
In several other studies, RANTES polymorphisms 
have been shown to affect the course of systemic lupus 
erythematosus [33], asthma [34], atopic dermatitis [35, 
36], diabetic nephropathy [37], coronary artery dis-
ease [38], recurrent acute rejection [39], and sickle cell 
anaemia [40]. However, little is known of their role in 
malaria. Since these variants have been shown to modify 
RANTES protein expression and low levels of RANTES 
have been implicated in malaria, this study was designed 
to determine the relation between these variants and the 
incidence of malaria among children living in an endemic 
area. Accordingly, the aim of this study was (1) to deter-
mine the allelic and genotype prevalences of RANTES 
gene polymorphisms, namely −403G/A, −28C/G and 
In1.1T/C in a population of children from a malaria-
endemic area (Iganga, Uganda); and, (2) to investigate the 
relationship between these polymorphisms with malaria 
incidence, parasite densities upon malaria diagnosis and 
the length of time to first re-infection following curative 
malaria treatment in this children’s cohort.
Methods
Study design and setting
This was a longitudinal study carried out in villages of 
Iganga district where children aged 6 months to 9 years 
were enrolled in order to determine malariometric indi-
ces during September 2008 and November 2009 towards 
preparation for the GMZ2 phase II malaria vaccine trial. 
From September 2008 to October 2008, a team of expe-
rienced home visitors approached households to system-
atically recruit children into the baseline study. Eligible 
children were enrolled into the study and followed up 
for a period of 1 year from November 2008 to November 
2009. Iganga district is situated in south-eastern Uganda, 
about 25 km to the north of Lake Victoria and lies at an 
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altitude of about 1138 m above sea level at latitude: 00°36′ 
North and longitude: 33°30′ East. Malaria transmission 
is this area is holo-endemic (intense and perennial), with 
transmission peaks seen following the major rains, which 
normally occur between April to June and September 
to December [41]. The annual entomological inocula-
tion rate (EIR) is not known, but is estimated to be 562 
infective bites per person per year in the neighbouring 
district of Tororo [42]. The study cohort was recruited 
from a community living within six villages of Iganga dis-
trict that are in close proximity to the malaria study clinic 
located at Makerere University Iganga/Mayuge Demo-
graphic Surveillance Site (MaK-DSS). No interventional 
studies were undertaken in this study area at the time this 
study cohort was assembled. Inclusion criteria of cohort 
study were as follows; (1) age 6  months to 9  years; (2) 
agreement to come to study clinic for any febrile episode 
or illness; (3) agreement to avoid medications adminis-
tered outside the study; (4) agreement to remain in study 
area during the twelve months follow up; (5) absence of 
known chronic disease and (6) written informed consent 
provided by parent or guardian. Severely malnourished 
children (below −3z scores of the median WHO growth 
standards) [43] were excluded. Follow-up started when 
children fulfilled all of the selection criteria and were 
free of symptomatic malaria. The villages were divided 
by convenience into active (nearby) villages and passive 
(more remote) villages.
Clinical assessment and determination of malaria 
incidence
A baseline survey was carried out and eligible children 
were enrolled into this cohort. At the time of enrolment, a 
physical examination was performed by study physicians. 
Baseline demographic data were collected from guard-
ians through a questionnaire-based interview, including 
malariometric indices. After the baseline survey, parents 
or guardians were instructed to bring their children to the 
malaria clinic based at Iganga Hospital whenever they felt 
unwell so as to avoid using any drugs not administered 
or approved by a study physician. A team of field work-
ers visited the enrolled children at home every fortnight. 
Those children found unwell were referred to the clinic 
for care or referral in case of severe illness. Malaria was 
defined as any P. falciparum parasitaemia plus a tympanic 
temperature of ≥38.0 °C or a history of fever (within the 
past 48  h). Thick and thin peripheral blood slides were 
stained with Giemsa and examined under a microscope. 
Parasite densities were calculated by counting the num-
ber of asexual parasites per 200 white blood cells (WBC) 
and assuming a WBC count of 8000/µL blood [44]. In 
addition, approximately 2 ml of blood sample were drawn 
and mixed with ethylenediaminetetracetic acid (EDTA) 
anticoagulant for subsequent analysis of DNA. Severe 
malaria was defined as having hyper parasitaemia (>5 % 
parasitized erythrocytes or >250,000 parasites/µL) and 
any of the danger signs including a core body tempera-
ture >40 °C, severe anaemia (haemoglobin <5 g/dl),hyper 
bilirubinemia (total bilirubin >2.5  mg/dl), prostration 
or weakness, impaired consciousness, respiratory dis-
tress, hypoglycaemia (blood sugar <40 mg/dL), acidosis, 
cerebral malaria or other additional sign as specified in 
definition for severe malaria [45, 46]. Children with con-
firmed malaria were treated with artemether-lumefan-
trine (Coartem®) according to the national treatment 
guidelines and those with severe malaria were admit-
ted for care at Iganga Hospital acute care unit. Time at 
risk for new infection was considered as the duration of 
study participation excluding 14 days after each episode 
of malaria.
Genomic DNA isolation
Genomic DNA was extracted from blood leukocytes 
using E.Z.N.A Blood DNA kit as outlined by the manu-
facturer’s protocol (Omega Bio-tek, USA). Approximately 
0.1  µg of genomic DNA was used for the genotyping 
assays.
Detection of RANTES gene polymorphisms
Polymorphisms were detected using polymerase chain 
reaction (PCR) amplification followed by restriction 
endonuclease digestion (RFLP) as described elsewhere 
[23, 47, 48]. For each reaction, 1–2 µL of the extracted 
DNA sample was incubated with DreamTaq DNA poly-
merase (Thermo scientific Inc, USA), 0.5  µM of each 
primer, 100  µM dNTPs and 2.0  mM MgCl2. After first-
round PCR, about 5  µL of each reaction was digested 
with restriction endonucleases and products were sub-
jected to electrophoresis on 2.5 % agarose gels (Thermo 
scientific Inc, USA) and visualized with ethidium bro-
mide. Genotypes were assessed by comparing the sizes of 
reaction products and controls after digestion.
Sickle cell genotyping
Sickle cell genotyping was based on characterization of 
haemoglobin AS (Hb AS) using nested PCR followed 
by RFLP as previously described by Parikh et al. [49]. In 
the first round, approximately 1–2 µL of the extracted 
DNA was incubated with DreamTaq DNA polymerase 
(Thermo scientific Inc, USA), 0.1  µM of each primer, 
200 µM dNTPs and 2.0 mM MgCl2.PCR products from 
the first round were subjected to a second amplification 
using DreamTaq DNA polymerase (Thermo scientific 
Inc, USA), 0.05 µM of each primer, 200 µM dNTPs and 
2.0 mM MgCl2. After second-round PCR, products were 
digested with restriction endonucleases and subjected to 
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electrophoresis on 2.5 % agarose gels (Thermo scientific 
Inc, USA) containing ethidium bromide. As described 
above, genotypes were assessed by comparing the sizes of 
reaction products and controls after digestion.
Data management and analysis
Data were cleaned, coded and entered into Microsoft 
Office Access ™ 2007. Descriptive statistics, Chi square 
tests and multivariate analysis were carried out using 
Stata12.0 (Stata Corp, College Station, TX, USA). Allele 
and genotype frequencies were calculated in accordance 
with the Hardy–Weinberg principle [50]. The association 
between RANTES genotype and malaria incidence was 
estimated using a multivariate negative binomial regres-
sion model. Initially, a bivariate analysis was performed to 
determine the relationship between each demographic/
clinical characteristic and malaria incidence. The final 
multivariate analysis model included the RANTES gen-
otype and all identified predictors of malaria incidence 
(age, malaria history, ITN use and the sickle cell trait). 
Adjusted incidence rates ratios (IRRs), P values and 95 % 
confidence intervals were calculated. The Wilcoxon rank 
sum test was used to compare the distribution of parasite 
densities across the different RANTES genotypes.
The effect of RANTES polymorphisms on the length 
of time to first re-infection following administration of 
anti-malarial drug was estimated using Kaplan–Meier 
non-parametric survival analysis. The log rank test was 
used to evaluate differences in the survival times between 
the different RANTES genotypes. Cox proportion haz-
ard regression model was used to control for other inde-
pendent predictors of length of time to re infection (age, 
malaria history and ITN use) and adjusted hazard ratios 
(aHRs) were calculated. For all statistical tests, two-sided 
p values of less than 0.05 were assumed to show statisti-
cal significance.
Ethical considerations
The clinical study and all study protocols were approved 
by the School of Medicine Research and Ethics Com-
mittee of the College of Health Sciences, Makerere Uni-
versity and by the Uganda National Council for Science 
and Technology (approval number HS 765). All partici-
pants provided written informed consent. All children 




A total of 980 children were screened for baseline studies 
to determine malariometric indices at Makerere Univer-
sity Iganga-Mayuge Demographic study site, Iganga Hos-
pital during September 2008 and November 2009 (Fig. 1) 
towards preparation for the GMZ2 phase II malaria vac-
cine trial (Fig.  1). Twenty-eight children were excluded 
because of guardian unwillingness to participate in the 
follow-up study. A sample of 434 for each arm was esti-
mated based on assumptions of malaria incidence of 
15  % in the active arm, with 95  % confidence interval, 
and ability to detect a vaccine efficacy of 30 %. However, 
assuming 20  % loss to follow up in the passive arm, a 
total sample of 518 was considered. Accordingly, of the 
remaining 952 children, 518 (54.4  %) were monitored 
passively and 434 (45.6  %) were followed up by active 
surveillance for 1  year and the incidence of malaria per 
child was determined. Eleven of the 434 children (2.5 %) 
would not provide an adequate blood sample for subse-
quent analysis of DNA. In order to determine the asso-
ciation between RANTES polymorphisms and malaria 
incidence, only 423 children who had been actively fol-
lowed-up were included in this study. The majority of 
study participants (96.7  %) were of Basoga ethnic back-
ground, while the rest constituted other tribes. Base-
line characteristics were as follows: mean age, 3.9  years 
(SD  ±  2.3); sex, 52.7  % male and 47.3  % female; mean 
haemoglobin, 12 g/dL (SD ± 1.5); the predominant blood 
groups, O+  (39.4  %) and B+  (30.4  %); 26.6  % carried 
the sickle cell trait. A majority of the study participants 
(94.6  %) reported to have had history of malaria in the 
6  months prior to study enrolment, 88.2  % reported to 
be using an insecticide-treated bed net (ITN) and 95.3 % 
reported having administered an anti-malarial drug pre-
viously (Table  1). No malaria episodes were registered 
among 217 out of 423 children (51.3  %) after a year of 
Fig. 1 Participant flow chart. Figure showing the 423 children 
recruited and actively followed-up who provided samples for RANTES 
gene polymorphisms analysis
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longitudinal follow-up. Among those with episodes (206 
children), the range was one to nine episodes per child 
with the distribution as shown in Fig. 2.
Distribution of RANTES polymorphisms
PCR for genotyping of the three RANTES polymorphic 
sites was performed for all individuals. The success rate 
was 96 %. Out of the 406 children who were successfully 
genotyped for the RANTES −403 G/A polymorphism, 
224 (55.2  %) had the RANTES GA genotype, 26.1  % 
carried the AA genotype while the remaining (18.7  %) 
had the wild type genotype. For the In1.1T/C polymor-
phisms, only 3.7 % carried homozygous mutations (CC), 
30.9  % carried the heterozygous (TC) genotype and a 
majority (65.4 %) had the wild-type (TT) genotype. The 
overall prevalence of the respective markers is shown in 
Table 2. No polymorphisms at all were seen for the −28 
C/G marker. The calculated allele frequencies for −403 
G/A and In1.1 T/C polymorphisms were in agreement 
with earlier reports [22] and the distributions of the gen-
otypes were close to the Hardy–Weinberg equilibrium. 
The two markers (In1.1 T/C and −403 G/A) showed a 
clear linkage disequilibrium, all cases with In1.1 muta-
tions also showed −403 mutations (Table 3).
Effect of RANTES polymorphisms on malaria incidence 
and baseline parasite densities
A single across groups test (ANOVA) was initially per-
formed to determine differences in the distribution 
of malaria incidence across the RANTES genotypes. 
Table 1 Demographic and  clinical characteristics of  the 
study population
Age in years (mean, SD) 3.92 ± 2.32
Sex, n (%)
 Male 223 (52.7)
 Female 200 (47.3)
Weight in kg (mean, SD) 15.47 ± 5.21
Blood group, n (%)
 O+ 166 (39.4)
 A+ 96 (22.8)
 B+ 128 (30.4)
 AB 27 (6.4)
 Non O (A+ B+ AB + others) 255 (60.6)
Sickle cell genotype, n (%)
 Wild type (Hb AA) 303 (73.2)
 Heterozygous (Hb AS) 110 (26.6)
 Homozygous (Hb SS) 1 (0.2)
Mean haemoglobin, SD (g/dL) 11.97 ± 1.46
Malaria history, n (%)
 Yes 400 (94.6)
 No 15 (3.5)
 Not sure 8 (1.9)
Reported ITN use, n (%)
 Yes 373 (88.2)
 No 50 (11.8)
Reported previous anti-malarial drug use, n (%)
 Yes 403 (95.3)
 No 14 (3.3)
 Not sure 6 (1.4)
Fig. 2 Incidence of malaria among the study participants. 51 % of the study participants had no malaria episodes during the longitudinal follow-
up. 5 % experienced 4–9 malaria episodes during the follow-up
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Crude malaria incidence rates/person/year were 0.91 for 
In1.1T/C wild-type, 0.94 for heterozygous and 0.73 for 
homozygous individuals. There was no significant differ-
ence in the distribution of malaria incidence across the 
three genotypes (P  =  0.76). Since there are known pre-
dictors of malaria incidence that needed to be adjusted 
for a multivariate negative binomial regression analysis 
was done in order to evaluate the association between 
RANTES polymorphisms and malaria incidence. An ini-
tial bivariate (unadjusted) analysis identified age, malaria 
history, ITN use and sickle cell trait (Table 4) as independ-
ent predictors of malaria incidence. After adjusting for 
the named confounders, the incidence rate for 1n1.1T/C 
heterozygotes was 1.1 times the incidence rate for wild-
type individuals (P = 0.55) and that of homozygotes was 
1.25 times the incidence rate for those without mutations 
(P = 0.6). Median parasite densities were as follows; wild 
type, 775 [inter quartile range (IQR) 225–2525] para-
sites/µL; heterozygote, 373 (IQR 150–2250) parasites/µL; 
homozygote, 2450 (IQR 925–11,000) parasites/µL. There 
was no difference in the median parasite densities between 
1n1.1T/C heterozygotes and wild types (P  =  0.26) or 
homozygotes and wild type individuals (P = 0.17).
For the RANTES −403G/A polymorphism, crude 
annual malaria incidence rates were 0.83 for wild-
type, 1.07 for heterozygotes and 0.97 for homozygous 
Table 2 Genotype and  allele frequencies of  the RANTES 
−403G/A, RANTES −28C/G and In1.1T/C polymorphisms






Genotype distribution, n (%)
 GG 76 (18.7) CC 403 TT 264 (65.4)
 GA 224 (55.2) CG 0 TC 125 (30.9)
 AA 106 (26.1) GG 0 CC 15 (3.7)
Allele frequency
 G 0.46 C 1.00 T 0.81
 A 0.54 G 0.00 C 0.19
Table 3 Distribution of RANTES In1.1/403 compound gen-
otypes among the study population
Wt wild type, het heterozygous, hom homozygous
a Any-homozygous or heterozygous






wt/a any 212 50.1
Table 4 Malaria incidence and other demographic characteristics
Variable Malaria Number new  
episodes
Crude incidence  
rate ratio
P value 95 % CI
No Yes
Age
 0.5–1 years 31 37 65 Reference – –
 >1–5 years 121 123 272 0.85 0.397 0.590–1.233
 >5–9 years 64 46 77 0.57 0.013* 0.371–0.887
Blood group
 A+ 56 41 77 Reference – –
 B+ 73 57 109 1.06 0.768 0.713–1.581
 O+ 78 87 184 1.38 0.086 0.955–2.000
 AB+ 10 17 36 1.66 0.091 0.922–2.997
 O− 1 1 4 2.49 0.306 0.433–14.340
 B− 0 1 1 1.24 0.878 0.074–20.906
AB− 0 1 1 1.24 0.878 0.074–20.906
Sickle cell genotype
 Wild type 158 145 289 Reference
 Heterozygous 64 46 110 0.78 0.394 0.755–1.427
Malaria history 201 199 412 7.33 0.008* 1.674–32.104
Reported anti-malarial drug use 206 197 386 1.68 0.247 0.698–4.043
Reported ITN use 184 189 377 2.69 0.001* 1.522–4.752
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individuals. There was no difference in the distribu-
tion of malaria incidence across the RANTES −403G/A 
genotypes (P  =  0.47). The adjusted incident rate for 
RANTES −403G/A heterozygotes was 1.09 times the 
incidence rate for wild-type individuals (P  =  0.66). 
Similarly, homozygotes showed a non-significant trend 
towards higher incidence rates than those carrying the 
wild type genotype (IRR =  1.16; P =  0.50) as shown in 
Table  5. Median parasite densities were as follows; wild 
type, 488 (IQR 213–2188) parasites/µL; heterozygote, 
563 (IQR 200–2800) parasites/µL; homozygote, 825 (IQR 
250–2450) parasites/µL. There was no difference in the 
geometric mean parasite densities between −403G/A 
heterozygotes and wild types (P  =  0.98) or between 
homozygotes and wild type individuals (P = 0.82). Since 
the two markers (−403G/A and In1.1T/C) demonstrated 
a clear linkage disequilibrium, another multivariate anal-
ysis was done with linking markers. There was no statisti-
cally significant association between any combination of 
mutations with malaria incidence (Table 6).
Effect of RANTES polymorphisms on time to first 
re‑infection
The impact of RANTES polymorphisms upon time to 
first re-infection after administration of malaria treat-
ment was also evaluated. The average time (weeks) to 
first re-infection was 13.4 for RANTES In1.1T/C wild-
type individuals, 12.7 for heterozygotes and 16.7 for 
homozygotes. There was no significant difference in the 
length of time to first re-infection between heterozygote 
and wild-type genotypes (P = 0.74) or between homozy-
gote and wild-type genotypes (P = 0.34). After adjusting 
HRs for age, malaria history and ITN use, the hazard for 
re-infection did not differ significantly between heterozy-
gotes and wild-type genotypes (HR  =  1.19; P  =  0.28) 
or between the In1.1C homozygotes and wildtypes 
(HR = 1.2; P = 0.67) (Fig. 3).
The average time (weeks) to first re-infection was 10.8 
for RANTES −403 G/A wild-type individuals, 13.4 for 
heterozygotes and 11.4 for homozygotes. The was no dif-
ference in the length of time to first re-infection between 
heterozygotes and wild-type genotypes (P  =  0.29) 
or between homozygotes and wild-type individuals 
(P  =  0.44). Additionally, no significant difference was 
seen in the hazard for re-infection for wild types vs hete-
rozygotes (HR = 1.31; P = 0.21) or between the wildtypes 
and −403A homozygotes (HR = 1.22; P = 0.42) (Fig. 4).
Discussion
In this study, the relationship between the presence 
of mutations in RANTES and incidence of malaria in 
a cohort of children living in a malaria-endemic area 
Table 5 Effect of RANTES polymorphisms on incidence of malaria
a Median parasite density (parasites/µL) at the time of diagnosis of symptomatic malaria
RANTES genotype Malaria Number new 
episodes
Adjusted incidence  
rate ratio





 GG 42 34 63 Reference – – 488 Reference
 GA 108 117 240 1.09 0.664 0.744–1.590 563 0.981
 AA 57 49 103 1.16 0.500 0.753–1.788 825 0.815
RANTES In1.1T/C
 TT 143 122 240 Reference – – 775 Reference
 TC 63 62 118 1.10 0.344 0.804–1.506 373 0.258
 CC 9 6 11 1.25 0.560 0.541–2.888 2450 0.166
Table 6 RANTES In1.1/403 compound genotypes and malaria incidence
RANTES In1.1/403  
genotype
Malaria No. of new  
episodes
Adjusted incident  
rate ratio
P value 95 % CI
No Yes
wt/wt 42 33 61 Reference – –
het/het 36 43 89 0.731 0.162 0.472–1.133
het/hom 25 18 28 1.171 0.609 0.640–2.142
hom/hom 8 6 11 0.935 0.879 0.394–2.220
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of Uganda was determined. Three SNPs (−28C/G, 
−403G/A and In1.1T/C) in the RANTES gene region 
were examined. These SNPs have been shown to modu-
late RANTES gene transcription in  vitro [22] and often 
demonstrated as important determinants of disease sus-
ceptibility and clinical outcomes for a variety of infec-
tions [22, 33–35, 37–40]. Yet, no relation with incidence 
of malaria has been reported before. Of the three previ-
ously described polymorphic sites, mutations were pre-
sent at only two sites, the −403G/A and the In1.1T/C 
markers. The frequencies of the −403 A and In1.1C 
alleles were 53.7 and 19.2 %, respectively. These rates are 
close to the frequencies of 43 and 20 % for −403 A and 
In1.1C, respectively, reported elsewhere among a popula-
tion of African Americans [22] and comparable to those 
found in Uganda [30] even though these studies were 
conducted among populations from different geographi-
cal settings. Also, notably, the results showed that the two 
markers occur in strong linkage disequilibrium; all cases 
with In1.1 mutations also showed −403 mutations. This 
finding is consistent with other reports that examined 
other populations in different study settings [22]. The 
rare −28G allele is found predominantly among Japanese 
[31] and Han Chinese populations [23], but scarcely dis-
tributed among Caucasian, African American [22] and 
Ugandan populations [30]. In this study, no mutations 
were found at the −28C loci consistent with studies con-
ducted elsewhere [22].
The In1.1C allele, which occurs in strong linkage dis-
equilibrium with the −403A allele, has been shown to 
lead to down-regulation of RANTES and lower levels of 
the cytokine [22, 23]. Low levels of RANTES have pre-
viously been associated with severe malaria [11, 12], 
but no direct relation with any incidence of malaria was 
seen before. In the present study, none of the RANTES 
mutations investigated showed any significant effect on 
malaria incidence, baseline parasite densities or time 
to first re-infection. In that context, the high frequency 
of the −403 mutation is surprising, since, as with many 
other polymorphisms such as sickle cell trait, malaria is 
cited as a factor that selects for a disease-related gene 
variant [5, 6]. Of course, RANTES is important in many 
other infections as well, but it is still hard to explain that 
lower levels of a chemokine could possibly be protective 
against common infections. The third marker, at −28, 
was found to be wild type in all children included in the 
Fig. 3 Kaplan–Meier plots for re infection by RANTES INT1.1 geno-
type (TT, TC or CC). Cumulative re-infections are plotted against 
weeks to the next infection. The study participants were actively 
followed-up with visits once every 2 weeks at their homes, to obtain 
information about re-infection. Using a Cox proportion hazard 
regression model, adjusting for age, malaria history and ITN use, the 
predictors of length of time to first re-infection for TT (wild- type); TC 
(heterozygous) and CC (homozygous) were not statistically different 
with p-value of 0.28 and 0.67, respectively
Fig. 4 Kaplan–Meier plots for re-infection by RANTES −403 geno-
type (GG, GA or AA). Cumulative re-infections are plotted against 
weeks to the next infection. Following an active follow-up with 
home visits once every 2 weeks, information about re-infection was 
obtained from the study participants. Using a Cox proportion hazard 
regression model, adjusting for age, malaria history and ITN use, the 
predictors of length of time to first re-infection for GG (wild-type); GA 
(heterozygous) and AA (homozygous) were not statistically different 
with p-value of 0.21 and 0.42, respectively
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present study. Absence of the −28 mutation, is a little 
surprising. This mutation up-regulates expression [22, 
23], and would confer better protection. However, higher 
levels of RANTES may be detrimental for other rea-
sons [32]. This is also in line with high prevalence of the 
−403 mutation, which reduces RANTES levels. Other 
studies confirm the higher incidence of the −403 muta-
tion in African populations [22, 28, 30] and could indi-
cate a selective force for low levels of RANTES. This is 
also consistent with other reports in which lower levels 
of RANTES have been observed in African populations 
compared to other populations [32]. Given the role of 
RANTES in protection against infectious diseases, these 
findings remain hard to explain.
In other disease conditions such as HIV where 
RANTES polymorphisms have been studied, there are 
still contrasting reports on the influence of these vari-
ants on susceptibility and disease progression. The strong 
down-regulatory activity on RANTES transcription that 
is afforded by −403 and In1.1 mutations has been shown 
to lead to increased susceptibility to HIV infection [29] 
and increased rate of disease progression [22, 48]. In 
other studies, no associations between these variants 
and HIV infection could be observed [28] and elsewhere, 
In1.1C homozygosity was associated with delayed dis-
ease progression among adult HIV-positive patients [30]. 
These findings suggest that the role of these variants in 
determining disease susceptibility and clinical outcomes 
in different study settings is still not clearly understood. 
Other markers within the RANTES gene that could 
potentially modulate RANTES expression may need to 
be evaluated in order to understand the observable dif-
ferences in epidemiological patterns. This may provide 
an insight into a clearer understanding of the role of 
RANTES polymorphisms in other diseases like malaria.
In the present study, previous history of malaria 
prior to recruitment was recorded as well. Most chil-
dren reported previous experience of malaria, and these 
showed a higher incidence rate than those who were 
earlier free from the disease. These findings may sug-
gest a genetic basis for susceptibility to malaria, which 
of course is most likely multifactorial, and dependent 
on other markers besides RANTES. A small number of 
children had many episodes of malaria during the study, 
up to nine during 1 year. At each incidence, the children 
were treated and cured from malaria, but they obviously 
get re-infected rapidly, and obviously do not develop pro-
tective immunity. At the same time, many children stayed 
free from malaria for the whole year, and the majority 
of those with malaria had only one episode. These chil-
dren live under very similar conditions, so they should be 
exposed to infectious mosquito bites at similar rates. In 
this study, there was no significant relation between the 
RANTES polymorphisms and malaria incidence. Given 
that malaria susceptibility involves a complex interplay 
of other genetic modifiers, such as sickle cell trait, G6PD 
deficiency, among others [5, 6], the impact of RANTES 
polymorphisms alone on malaria incidence may not be 
evident. Sickle cell heterozygotes showed lower incidence 
of malaria compared to those with normal haemoglobin. 
The O+ blood group type known for protection against 
severe P. falciparum malaria [51, 52] instead showed a 
trend towards higher incidence of malaria, a variation 
that may relate to differences in the impact of the O+ 
blood group type upon severe malaria rather than the 
actual susceptibility to malaria. Controlling for these fac-
tors still yielded no significant associations between the 
RANTES polymorphisms and malaria incidence. Thus, 
additional studies evaluating other markers that could 
potentially modify RANTES gene expression along-
side other biological interactions between other genetic 
modifiers and their impact on malaria susceptibility may 
provide a clearer understanding of these less dramatic 
associations.
There were some limitations to this study. Information 
on known preventive measures and prior anti-malarial 
drug use was obtained by questionnaire-based inter-
views, which could have influenced the outcome of the 
multivariate analysis since known protective measures 
unexpectedly scored as risk factors of malaria. Addition-
ally, this study looked at a single gene (RANTES). Addi-
tional modifying genetic factors other than the sickle cell 
trait were not adjusted for.
Conclusions
Results of this study show that the −403A mutation 
occurs in nearly half the study population and In1.1C 
allele occurs in one in every four children. Despite the 
high frequency of these mutations, there was no clear 
association with malaria incidence. Since both polymor-
phisms lead to down-regulation of RANTES expression 
and expected lower levels of RANTES, these findings 
remain hard to explain. There were no mutations at the 
−28 marker. This marker has previously been shown to 
lead to increased RANTES expression. Thus, absence of 
−28 mutation in the Uganda study population is quite 
surprising. Evaluating other markers that could poten-
tially modulate RANTES gene transcription may pro-
vide further explanations to these less dramatic findings. 
Additionally, since there are several other markers that 
have been implicated in pathogenesis of malaria, the 
impact of RANTES polymorphisms alone on malaria 
incidence may be difficult to evaluate. Therefore, other 
larger studies looking at the interplay between other 
genetic modifiers and malaria susceptibility may provide 
clearer understanding of these findings.
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